GREECE

CERVICAL CANCER PROFILE


Morbidity and Mortality

TOTAL DEATHS, FEMALE (2019): **62 200**



Primary Prevention

HPV vaccination programme coverage among girls (2020)



HPV is included in the national vaccination programme but coverage data is not available

Secondary Prevention

National screening programme	
for cervical cancer exists (2021):	Yes
Primary screening test used (2021):	cytology
Target age range of programme (2021):	while sexually active
Programme/guidelines exist to strengthen early de	tection
of first symptoms at primary health care level (2027	I): Yes
Clearly defined referral system exists from primary	care
to secondary and tertiary care (2021):	Yes

Treatment and Supportive Care

National guidelines on cervical cancer management	
exist (2021):	No

Cancer diagnosis and treatment services generally available (2021):

Yes
Yes
Yes
Yes
Yes


HPV vaccination programme (2020):

HPV included in national vaccination programme:	Yes
Scale of vaccination programme:	National
Year of introduction:	2009
Primary target cohort:	11-12 years

Related risk factors:

Tobacco use prevalence, women aged 15+ years (2020):	27%
Condom use at last high-risk sex (-):	ND
HIV incidence per 1000, women aged 15+ years (2020):	0.03

Screening for cervical cancer (2019)



9 in 10 women have been screened for cervical cancer in the last 5 years

Number of radiotherapy units per 10 000 cancer patients (2021):	9
Number of brachytherapy units per 10 000 cancer patients (2021):	2

Number of medical staff (per 10 000 cancer patients):

Radiation oncologists (2019):	ND
Medical physicists (2019):	68
Surgeons (2013):	1668
Radiologists (2019):	493
Nuclear medicine physicians (2019):	ND

Palliative care for patients with NCDs in the public health system generally available (2021):

In primary health care facilities:	No
In community or home-based care:	No

Reported annual opioid consumption excluding methadone - in oral morphine equivalence per capita (2017): 118mg

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15

70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age

90% of women identified with cervical disease receive treatment

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls)
+ Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions